objective To estimate the Brazilian direct and indirect costs of human visceral leishmaniasis (VL) in 2014.
Introduction
Human visceral leishmaniasis (VL) is a neglected illness that remains an important public health issue around the world, affecting economically vulnerable populations in more than 80 countries [1] . Around 90% of the cases registered in Latin American occur in Brazil. In the country, 3453 new cases of such illness were reported in the Notifiable Diseases Information System (SINAN) in the year of 2014, after removal of relapse and transference registrations. In that year, the incidence corresponded to 1.7 cases per 100 thousand residents and 6.9% lethality [2] .
If untreated, VL is a fatal illness. It is one of the main causes of mortality among the neglected tropical illnesses in Brazil [3] . It is strongly associated with poverty and responsible for high direct and indirect costs. Despite the considerable health burden posed by VL, there have been few attempts to quantify its economic impacts on affected communities [4, 5] .
Diagnostics, treatment and care of patients with VL are provided by the public healthcare system (Sistema Unico de Sa ude -SUS) in Brazil and represent the direct costs. The identification of indirect costs is also relevant, considering that VL is associated with high mortality and an important cause of productivity loss.
Cost-of-illness studies have the potential of informing decision-makers on the relative impact of diseases at the population level, assisting them in making projections of future healthcare costs and in resource allocation decisions [6] . To date, no studies on the costs of VL illness, including societal and the healthcare provider perspectives, have been carried out in Brazil. We aimed to estimate the costs of VL in Brazil by taking into consideration both direct medical costs and productivity losses due to morbidity or premature mortality.
Methods

Study design
A study of VL costs was carried out in Brazil following the perspective of the SUS and society, considering the number of cases reported in the SINAN in the year of 2014. We used a top-down approach to quantify direct costs related to diagnostics, treatment and care provided to patients with VL. In a top-down approach, statistical databases and registries obtained in the national official systems are used to estimate the costs for a given illness, providing aggregate data at the regional or national level.
Indirect costs involved the lost work days due to hospitalisation (morbidity) and lost production potential due to premature mortality. Indirect costs were estimated through the human-capital method, which transforms days of absence from work, death or illness into monetary units by means of the application of average remuneration [7] . The calculation multiplies the period of absence of the individual from work with the salary proportional to the period.
Current VL case management in Brazil and assumptions
SUS offers diagnosis for suspected cases of VL and ambulatory care or hospitalisation for the confirmed cases. According to the MoH recommendations, clinically suspected cases of VL can be confirmed through epidemiological or laboratory criteria. The patient must test positive using at least one of the following assays: direct parasitological examination or parasite isolation in culture from bone marrow aspirate and the indirect fluorescence antibody test (IFAT) or the rapid test for anti-rK39 antibody detection [8] . In 2014, the MoH provided the Kalazar Detect â rapid test. Once the VL case is confirmed, other tests should be performed (Box 1) to identify conditions that determine the patient's severity and the risk of evolving to death [9] . Prognostic assessment directs the therapeutic management, because the choice for a specific treatment depends on the clinical situation severity of each patient. Patients with a worse prognosis should be hospitalised. The meglumine antimoniate is the first-line treatment of VL in Brazil and is administered intravenously every day for 20 days at a dosage of 20 mg/Sb +5 /kg/day, with a maximum dosage of three vials per day. During the period of treatment with meglumine antimoniate, electrocardiographic and laboratorial tests are used to monitor the evolution and to identify possible drug toxicity. According to the MoH, treatment with meglumine antimoniate can be performed at ambulatory or hospital care, depending on the patient's severity [8] .
Liposomal amphotericin B constitutes the first-choice treatment in Brazil for the subgroup of patients with the worst prognostic and highest risk of death. The treatment regimen is 3 mg/kg/day intravenously for 7 days. The liposomal amphotericin B (3 mg/kg every two weeks) is also used for secondary prophylaxis of patients coinfected with Leishmania-HIV [10] . It is recommended the amphotericin B deoxycholate to treat patients presenting hypersensitivity or therapeutic failure to the meglumine antimoniate, who do not follow any of the indication criteria of liposomal amphotericin B use. The drug dose is 1 mg/kg/day intravenously for 14 days with a maximum dosage of 50 mg/day [8] .
The MoH recommendations were used to identify relevant costs related to the VL in Brazil and to define the assumptions to estimate them (Box 1).
Definition of cases and sources of information
Considering that VL is a notifiable illness in Brazil, new cases of such disease reported at SINAN in 2014 were defined as study cases, and relapses and transfer records were not considered [11] . MoH provided the non-nominal SINAN database for VL, referring to 2014, after removal of duplications and inconsistences. In 2014, the SINAN database for VL was comprised of 10 278 records, of which 3731 were confirmed cases. After removal of 225 relapses and 158 transference registrations, the database was comprised of 9895 new suspected cases of VL, of which 3453 registrations were new confirmed cases. The SINAN was used as the source of epidemiological parameters to determine direct and indirect costs. The epidemiological parameters are presented in Table 1 .
Direct medical costs were assessed based on the values paid and reimbursed by SUS for different items, which were obtained in the following sources: hospital information system (SIH-SUS), management system of the SUS table of procedures, medications, orthoses, prostheses and materials (SIGTAP), health prices index (BPS), and information provided by the MoH. The unit values for all items are presented in Table S1 .
Estimate of costs
Costs were obtained in Brazilian Reais (R$) for 2014. Costs regarding other years were adjusted for the official inflation rate estimated by the accumulated National Only the costs of drugs recommended by the MoH were obtained for VL treatment. The registers of cases using other drugs were only considered for hospitalisation costs. The number of meglumine antimoniate vials was determined following the drug dose and number of patients in each weight range corresponding to the use of one, two or three vials. For other drugs, the drug dosage based on the average weight of patients (36.4 kg) reported at SINAN. For patients treated with meglumine antimoniate, the rate of hospitalised patients was estimated based on data from a previous study (Coura-Vital et al., 2014) [14] . An amount of patients with higher severity scores (at higher risk of evolving to death) was hospitalised (88%), and the other part was treated at ambulatory care (12%). Patients treated with liposomal amphotericin B, amphotericin B deoxycholate and other drugs were hospitalised. Hospitalisation Hospitalisation cost was estimated according to the proportion of hospitalised patients for treatment with meglumine antimoniate and for patients treated with liposomal amphotericin B, amphotericin B deoxycholate and other drugs. The costs of this category considered the value paid by MoH for Hospitalisation Authorisations (AIH) and performance of medical consultations after hospital discharge (end of treatment), with the exception of those patients that evolved to death. Four medical consultations were considered for patients' follow-up after 30, 60, 90 and 180 days to detect possible relapses. Additional measures for VL treatment such as hydration, antipyretics, antibiotics, hemotherapy and nutritional support, when necessary, would explain the patient's hospitalisation; therefore, their costs would be included in the hospitalisation cost. Ambulatory care
The following procedures were conducted to the proportion of patients treated with meglumine antimoniate at ambulatory care, considering a 20-day treatment: -Daily procedures of drug administration (20 procedures) -Weekly medical consultations for clinical follow-up during the treatment (three procedures) -Weekly tests to identify a possible drug toxicity (three procedures): ECG (for patients older than 40 years old); tests to monitor liver and kidney functions (the same ones used in other performed tests, as previously described) and pancreatic function (amylase and lipase). Patients at ambulatory care considered the use of antipyretics available at SUS (dipyrone):
-A dipyrone vial of 500 mg/ml of oral solution for patients aged up to 12 years old; -Thirty dipyrone tablets of 500 mg for patients older than 12 years old. Four medical consultations were also considered after conclusion of VL treatment for patients' follow-up after 30, 60, 90 and 180 days to detect possible relapses.
Secondary prophylaxis
The confirmed cases of VL in SINAN with Leishmania-HIV coinfection conducted a secondary prophylaxis with liposomal amphotericin B for one day, every two weeks.
Productivity loss
We assumed that all hospitalisations created a period of work absence, because the subject at productive age (minimum age of 18 and maximum of 65 for men and 60 for women) was in the condition of VL hospitalised patient or in the condition of companion of another hospitalised patient with such disease (children or elderly). After hospital discharge, hospitalised patients were absent of work for 15 days for home recovery.
To estimate the productivity loss due to morbidity (hospitalisation), the number of hospitalised patients was the same used to measure the direct medical costs, with the exception of those that evolved to death.
Consumer Price Index (IPCA) [12] . The costs were converted to American dollars (US$) at the exchange rate for 2 June 2014 (one American dollar = 2.26 Brazilian Reais) [13] .
Direct costs
The direct costs of VL management were divided into six cost categories: (i) diagnostic VL, (ii) other tests performed, (iii) treatment, (iv) hospitalisation, (v) ambulatory care and (vi) secondary prophylaxis. Costs were estimated by multiplying the use of resources in terms of consultations carried out, tests performed, drugs provided, number of hospitalisations by the official prices. For patients treated with meglumine antimoniate at ambulatory care and for patients who performed a secondary prophylaxis with liposomal amphotericin B, the costs of medication administration were also estimated.
The number of vials used for each patient was identified considering the dosages recommended based on the patient's average weight obtained through the SINAN (36.4 kg). For the meglumine antimoniate, the amounts of patients in each weight range corresponding to the use of one, two or three vials were obtained. Thus, according to the VL treatment regimen for a patient, we found that 40 vials of meglumine antimoniate or 21 vials of liposomal amphotericin B or 14 vials of amphotericin B deoxycholate were used.
All patients treated with liposomal amphotericin B, amphotericin B deoxycholate and other drugs were hospitalised. The rate of patients treated at hospital had to be estimated for meglumine antimoniate, considering that the SINAN does not include variables associated with the level of care in which the VL treatment was performed. We used data from a study that developed a system of scores to determine the death prognostic due to VL, in which the highest scores indicated more severity [14] . ' ¶SINAN includes an option to record 'other used drugs,' without specification, which do not have current recommendations yet. kThe rate of deaths by VL was calculated among the confirmed cases (6.7%) to determine the direct medical costs related to care (number of follow-up consultations after VL treatment conclusion at hospitalisation and ambulatory care) and medical indirect costs related to the productivity loss due to morbidity (number of patients who were absent of work due to hospitalisation). **The hospitalised patients are comprised of 1757 patients treated with antimoniate, 704 with liposomal amphotericin B, 415 with amphotericin B deoxycholate and 191 with other drugs. There is no information about the performance of the VL treatment for some of the confirmed cases of VL.
Based on these data, 88% of the patients had higher scores (37% of the patients with 2 and 3 scores and 51% with 4 or higher scores) and were hospitalised for treatment, and 12% of the patients with 0 and 1 scores were treated at ambulatory care. The average value of AIH for VL, registered in the SIH-SUS, obtained through DATA-SUS was considered as the hospitalisation cost based on non-nominal data [15] .
Costs of secondary prophylaxis with liposomal amphotericin B were obtained through the use of this drug on a daily basis, every two weeks, for the confirmed cases of VL with Leishmania-HIV coinfection. Considering the costs were estimated for a one-year period (52 weeks) in this study, 26 procedures of drug administration and 78 vials for a patient's secondary prophylaxis (three vials per day based on the considered average weight of 36.4 kg) were taken into consideration.
Besides total costs, the mean cost of diagnostic, treatment and medical care provided to a patient with VL was calculated through the sum of mean costs for each category. The mean cost of secondary prophylaxis for a patient with Leishmania-HIV coinfection was also calculated.
Indirect costs
Indirect costs related to productivity loss due to premature mortality and morbidity were estimated. The human-capital method was used. The potential years of work lost due to premature mortality by VL were estimated to obtain costs related to the productivity loss due to premature mortality, which were all calculated from the deaths by VL registered in the SINAN and their distribution per age.
For estimating the potential years of work lost, the minimum and maximum ages of a subject's productive capacity in the year of 2014 were fixed. The minimum age was 18 years to enter the work market, and the maximum ages for retirement were 65 years for men and 60 for women, according to the Brazilian labour regulations [16] . To calculate the potential years of work lost, the ages of productive capacity were the limits and the calculation only considered deaths that occurred in these age ranges, which were divided into sex. The unpaid wage estimation throughout the period used the minimum monthly wage practiced in Brazil in 2014 that corresponded to BRL 724.00 (US$ 320.35) [17] . Thus, the gross yearly wage of a subject in such year was of BRL 9653.33 (US$ 4271.38), which considered twelve monthly wages of BRL 8688.00 (US$ 3.844.25), the thirteenth wage of BRL 724.00 (US$ 320.35) and the vacation bonus of BRL 241.33 (US$ 106.78). The wage loss regarding the potential years of work lost was obtained based on such data.
Costs of productivity loss due to morbidity were obtained based on the days of work absence of the hospitalised patients or their companions, without including the number of patients who died. The calculation of the productivity loss of a hospitalised patient used the daily wage value of BRL 24.13 (US$ 10.67) [17] multiplied by the sum of the average of hospitalisation days in the SUS due to VL (14.3 days) and of the period in which the patient remained at home recovery after hospital discharge, before returning to work (15 days).
Sensitivity analysis
A sensitivity analysis was conducted. For direct and indirect costs, the parameter 'Number of patients treated with meglumine antimoniate at hospital level' was varied, considering two situations: one where only patients with score 4 or higher are hospitalised (51%, corresponding to 1018 cases) and another where all the VL patients treated with meglumine antimoniate (100%, corresponding to 1997 cases) were treated at hospitals. With regard to costs, the HIV test and dipyrone drug value varied, considering there were different values of acquisition throughout the year of 2014. The other tests and drugs were not varied because they occurred in a single acquisition in the study year.
Ethical review
The Research Ethics Committee of the School of Medicine of University of Brasilia (CAAE number 55584316.8.0000.5558) approved this study.
Results
In 2014, 9895 suspected cases of VL and 3453 confirmed cases were registered in Brazil. Of these, 2283 (66.1%) were healed and 230 (6.7%) died of VL. Outcomes of the other cases were registered as abandonment, death by other causes and transfers. Most of the cases occurred in men (64%) and the most affected age range was 20-49 years (32% 19 ) and secondary prophylaxis cost US$ 344 042.12. Most costs were associated with hospitalisation (40%), followed by VL treatment (22%) and secondary prophylaxis (18%). The direct medical costs of VL are presented in Table 2 .
The mean cost for diagnostic, VL treatment and hospital and ambulatory care for a VL case was US$ 500.91 (499.95 to 504.57), and the mean cost of secondary prophylaxis for a case with Leishmania-HIV coinfection was US$ 1470.27. There were 230 deaths by VL among the confirmed cases in 2014. Of these, 128 occurred in subjects at productive age, of whom 29 were women aged 18 to 60 years and 99 were men aged 18 to 65 years. Regarding loss of productive capacity due to the premature mortality for VL, 489.5 years among women and 2184.5 among men were lost, resulting in 2674 years of potentially years of work lost of VL at productive age who died. In wage terms, US$ 11 421 683.37 were lost due to premature VL mortality ( Table 3) .
The productivity loss due to morbidity was obtained for 2862 hospitalised patients for VL treatment (with the exclusion of 205 deaths in the total of 3067 hospitalised patients). Thus, 83 856.6 work days were lost and there was a wage lost of US$ 895 336.18. The total of indirect costs related to the productivity loss was US$ 12 317019.55.
The total cost of VL in Brazil was US$ 14 190 701.50 (US$ 14 189 150.10 to 14 199 940.53). Around 80% of the costs correspond to productivity loss due to premature mortality.
These costs were obtained considering that 88% of the patients treated with meglumine antimoniate and all patients treated with liposomal amphotericin B, amphotericin B deoxycholate and other drugs, were hospitalised. The sensitivity analysis indicated a decrease of 6.9% in the direct medical costs and 1.8% in indirect costs, when we considered 51% of the hospitalised patients treated with meglumine antimoniate. There was a 2.3% increase in the direct medical costs and 0.6% indirect costs when 100% of these patients were hospitalised (Table 4) .
Discussion
VL is one of the neglected tropical diseases prioritised by WHO to develop strategies that aim to prevent, control and reduce the disease burden, not only regarding the direct burden of morbidity and mortality but also regarding the social and financial burden imposed by it and thus contributing to the maintenance of the poverty cycle [18] . Despite the high burden of these diseases, only a few economic studies were done, among them studies on the costs of neglected diseases [5] .
Studies on disease costs are useful to provide support on the decisions of health resources allocation, because they report to managers the value of economic losses related to a disease and its distribution by cost categories. However, methodological limitations regarding the kind of study are identified. Examples include the diversity of approaches used in the estimate of costs, which compromise the comparability of study results; and the possibility of cost underestimation based on official systems such as SIH, which is limited to information in the SUS range, without considering costs paid by citizens or covered by health insurance [19] .
Similarly, the use of the amounts paid by the SUS for cost estimates in cost-of-illness studies represents a limitation, considering that the values may be outdated, which would lead to an underestimation of costs. However, it is important to note that, although outdated, these data reflect the reality of the amounts paid and reimbursed by SUS in the context of the country as a whole. If amounts paid by a specific institution are used, even if we were using more updated values, the reality of the country may not be properly represented.
Another methodological limitation of this kind of study is related to the assumptions for cost estimate, which †Mean cost for each category was calculated by means of the division between the total cost of the category and the number of cases using the resources. ‡Other drugs without current recommendations of the MoH for VL treatment. might under or overestimate them. In this study, assumptions were based on the current recommendations of MoH in a way to fulfil lacking information regarding the care line to the patient with VL, which are not included in the SINAN. For example, the category of direct costs 'treatment' included only the costs of drugs recommended by the MoH. However, there are records of use of other drugs (without indicating which drugs) in the SINAN database. For the total number of patients treated with these other therapeutic options, not included in the current recommendations of the MoH, only the cost of the hospital care required to perform the treatment was assumed. This may lead to an underestimation of costs.
VL is endemic in Brazil. Currently, 21 of 27 federative Brazilian units report cases [8] . Therefore, this study uses the top-down approach based on national data of illness notification to reflect the reality of a country as a whole. Similarly, the unit costs were obtained from data of national official systems, which provide values paid or disbursed by the MoH for the used resources. Top-down approach requires relatively few resources but provides a limited level of detail compared to micro-costing, which provides a high level of detail but is resource and dataintense. The main advantage of the top-down approach is its external validity, as it uses national data sources, which cover regional and institutional variations. Drummond et al. recommended using the micro-costing method whether the economic evaluation is being undertaken alongside a prospective clinical study, because it is possible to have access to individual patient data. In this way, the choice of the specific approach depends on the level of precision required by the study and the feasibility of obtaining the data [7, 20] .
The analysis of costs from the perspective of the SUS showed that the largest part (40%) of the estimated direct medical costs was related to hospitalisation as a consequence of the AIH mean value. It comprises the value corresponding to professional and hospital services [21] .
Another relevant category about direct medical costs was related to the secondary prophylaxis performance for patients with Leishmania-HIV coinfection. HIV infection increases the risk of developing VL, reduces the probability of therapeutic response and increases the probability of VL relapse considerably. The secondary prophylaxis demonstrated a protective effect to avoid the occurrence of VL relapse in co-infected patients [22] .
Around 80% of the costs identified in this study correspond to productivity loss due to premature mortality as a result of the 128 deaths by VL that happened at productive age.
Studies of VL costs developed in other endemic countries were identified. The cost of diagnostic and VL treatment of a paediatric patient in Morocco, in the North of Africa, was US$ 520 (US$ 316-658) [23] . A study developed in Sudan found a mean cost per patient of US$ 450 *The sensitivity analysis was carried out for the parameter variation 'Number of patients treated with meglumine antimoniate at hospital level.' In this study, costs were obtained considering that 88% of the patients treated with meglumine antimoniate were hospitalised. For variation, direct and indirect costs were calculated considering that 51% and 100% of the patients were hospitalised. All the other patients treated with other available therapeutic options were hospitalised.
(US$ 387-544), including direct and indirect costs, and the productivity loss was estimated only with regard to morbidity [24] . In both studies, the costs were estimated through the micro-costing. However, it is worth note that the comparability of study data on disease costs between several countries is limited due to the differences in the most used methodologies, population characteristics and organisation of health services [19] . In 2014, 95% of the confirmed VL cases were treated with at least one of the therapeutic options. In this study, costs were estimated considering the hospitalisation of all patients treated with the other therapeutic options and of 88% of patients treated with meglumine antimoniate. As costs related to hospitalisation corresponded to most of the direct costs identified in this study, there was an important decrease in such costs when only half of these hospitalised patients were considered. Nevertheless, hospitalisation of all confirmed cases of VL would be essential to ensure proper clinical follow-up of the patients through the opportune conduction of tests and use of additional measures to the specific treatment. According to the WHO, decisions on therapeutic conducts should be established based on guidelines of endemic countries, considering some aspects like the fact that treatment should be administered following the supervision of a medical professional and that, in many cases, the support treatment could be necessary before the beginning of therapy [25] .
In this study, the highest component of VL costs is related to productivity loss due to premature mortality of subjects affected by the disease at productive age. Considering that the MoH prioritises the decrease in lethality by VL as one of the main strategies for controlling the disease in Brazil, this cost study may direct the interventions to be performed for reaching this strategy and predicting the decrease in costs as a consequence of the use of these interventions.
In Brazil, no cost-effectiveness studies on therapeutic strategies for VL have been identified up to now, only for diagnostic tests. Among the diagnostic tests evaluated in that study (direct examination of bone marrow aspirate, IFAT, Kalazar Detect, IT LEISH, DAT-LPC and PCR), the first three were also considered in the present cost of illness, as they are the tests currently recommended by the MoH. The results showed that DAT-LPC was the most cost-effective method in relation to the other tests evaluated, evidencing the importance of reviewing the current recommendations on the diagnosis of VL in Brazil [26] . In this sense, a cost-effectiveness study of the VL treatment is being conducted to identify the most suitable therapeutic alternative in this country to reduce the lethality of the disease. These studies aim to support the decision-making process by public health managers in a way to improve the care line provided to the patient with VL.
Conclusion
Data identified in this study reinforce the importance of VL as a severe public health issue, because it is a disease associated with poverty with high direct and indirect costs. The largest cost component is related to the productive capacity loss due to premature mortality, which indicates the need of interventions directed to the lethality decrease by the disease.
